KOSDAQBiotech & Pharma176750

DuChemBio

₩5,280▼ 0.94%2026-11-18 close
Market Cap
₩150.4B
Turnover
₩400M
Volume
70K
Shares out.
28.5M
PER
21.9×
PBR
2.9×
EPS
₩245
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Diagnostic Profit Recovery Meets CDMO Build-out

Diagnostic-led profit recovery has kept quarterly sales at high levels, while net profit trends and the capital needs of the CDMO build-out remain the variables to track.

  1. 1

    Operating profit rose 46.6% in 2025 to KRW 7.44 billion, and the operating margin reached 19.3%, the highest of the 2023-2025 period.

  2. 2

    Q2 2026 revenue of KRW 11.2 billion was reported as the company's highest quarterly sales, and Q3 2026 revenue of KRW 11 billion rose 11.1% year-over-year.

  3. 3

    Net profit attributable to controlling shareholders fell 18.9% to KRW 6.48 billion in 2025 and has risen for two consecutive quarters since the Q1 2026 low.

  4. 4

    The company reported a 96.3% share of domestic Alzheimer's diagnostic output by production value for 2025.

  5. 5

    The Jeongeup CDMO plant is planned with KRW 34.3 billion of investment, targeting construction start in June 2027 and commercial production in the second half of 2029.

02

Business structure

DuChemBio produces and sells radiopharmaceuticals, and its earnings center on diagnostic radiopharmaceuticals. Its main products are the Alzheimer's diagnostics NeuraCheck and Vizamil, the Parkinson's diagnostic 18F-FP-CIT, and the prostate cancer diagnostic Prostasic, alongside the established cancer diagnostic FDG.

According to the company's H1 2026 results (announced August 18, 2026), FDG sales were KRW 10.8 billion, while the three products covering Alzheimer's, Parkinson's and prostate cancer totaled KRW 7.6 billion, lifting their share of total revenue from 28.9% to 36.2%.

The company says it holds a share above 94% of the domestic amyloid PET diagnostic market. Its production base consists of 12 manufacturing sites, five of which are GMP-certified, and because radioisotopes have short half-lives, nationwide supply coverage is cited as a competitive asset.

In the pipeline, the tau-targeting diagnostic 18F-MK-6240 is in process development, and the company holds the neuroendocrine tumor therapy 177Lu-DOTATOC, co-developed with Germany's ITM, as well as in-house therapeutic candidates DCB001 and DCB002.

Its wholly owned subsidiary Radio DNS Labs received a US patent decision for an AI-based early diagnostic imaging technology, which the company links to a North American path for its Parkinson's diagnostic.

Its largest shareholder, Geoyoung, held 51.55% as of end-December 2025, and the largest shareholder group held 60.87% in total.

The company holds a leading share in the domestic Alzheimer's diagnostic market, while the competitive picture in therapeutic CDMO will become clearer as the Jeongeup plant approaches operation.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.9B₩1.9B19.2%
2025Q4₩10.7B₩3B27.9%
2026Q1₩9.7B₩1.3B12.9%
2026Q2₩11.2B₩1.9B17.2%
2026Q3₩11B₩1.9B17.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩34.7B₩5.3B₩4B15.1%18.4%126.1%
2024₩35.6B₩5.1B₩8B14.3%18.6%51.5%
2025₩38.6B₩7.4B₩6.5B19.3%13.2%57.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-filed basis, annual revenue was KRW 34.7 billion in 2023, KRW 35.6 billion in 2024 (up 2.6%) and KRW 38.6 billion in 2025 (up 8.3%), rising in both 2024 and 2025, with 2025 the largest year of the three.

Operating profit fell from KRW 5.26 billion in 2023 to KRW 5.08 billion in 2024 (down 3.4%), then rose to KRW 7.44 billion in 2025 (up 46.6%), making 2025 the largest year. The operating margin moved from 15.1% in 2023 and 14.3% in 2024 to 19.3% in 2025, the highest of the three years.

Net profit attributable to controlling shareholders was KRW 4 billion in 2023, KRW 7.99 billion in 2024 (up 99.8%) and KRW 6.48 billion in 2025 (down 18.9%), with 2024 the largest year.

In 2024 operating profit declined while controlling-shareholder net profit nearly doubled, and in 2025 the reverse occurred, so the two measures moved in opposite directions in both years. Non-operating items and tax lines are the likely source of that gap, and their amounts are items to verify in the annual report.

Net profit including non-controlling interests was KRW 4 billion, KRW 7.99 billion and KRW 6.48 billion over the same years.

The debt-to-equity ratio fell from 126.1% in 2023 to 51.5% in 2024 before edging up to 57.8% in 2025, and at end-2025 total equity was KRW 49.2 billion, all attributable to controlling shareholders, against total liabilities of KRW 28.4 billion.

Operating cash flow was KRW 8.44 billion in 2023, KRW 7.03 billion in 2024 and KRW 9.94 billion in 2025, the largest of the three years.

On a quarterly basis, revenue moved from KRW 9.93 billion with operating profit of KRW 1.9 billion in Q3 2025 to KRW 10.7 billion (up 7.6% quarter-on-quarter) with operating profit of KRW 2.99 billion (up 57.1%) in Q4 2025, when controlling-shareholder net profit was KRW 3.32 billion.

Q1 2026 marked the low point, with revenue of KRW 9.7 billion (down 9.2%), operating profit of KRW 1.26 billion (down 57.9%) and controlling-shareholder net profit of KRW 873 million.

In Q2 2026, revenue rose to KRW 11.2 billion (up 15.4%) and operating profit to KRW 1.93 billion, and the company attributed operating profit growth trailing revenue growth to a base effect from one-time high-margin sales in the prior year, together with higher bad-debt provisions and recurring R&D expenses.

Q3 2026 revenue was KRW 11 billion (down 1.5% quarter-on-quarter, up 11.1% year-over-year), operating profit was KRW 1.9 billion (down 0.2% year-over-year), and controlling-shareholder net profit was KRW 1.55 billion (up 7.7% year-over-year). Controlling-shareholder net profit for the last four quarters totaled KRW 6.94 billion.

05

Industry analysis

Demand for dementia diagnostics has grown visibly since 2025, when Leqembi prescriptions began. According to company data published in September 2026, the growth rate of production value for its Alzheimer's diagnostics rose from 12% in 2024 to 55% in 2025.

A May 2026 report expected Eli Lilly's Kisunla to receive domestic approval within the year, which would sustain demand for amyloid PET used to select patients before treatment.

The government launched a pilot dementia asset-management service in April 2026, and the Ministry of Health and Welfare set reform of the early diagnosis system as a core task.

The company argues that radiopharmaceutical production carries high fixed costs in cyclotrons, GMP facilities and radiation specialists, so unit costs fall as utilization rises.

On barriers to entry, Vice Chairman Kim Jong-woo said in a January 2026 interview that latecomers would struggle to win meaningful share in an established market, and he added that no dementia-diagnostic radiopharmaceutical was in clinical trials globally, according to his knowledge.

The domestic position is reflected in a share above 94% of the amyloid PET diagnostic market, reported by the company in May 2026, and a 96.3% share of 2025 production value, reported in September 2026.

The prostate cancer diagnostic Prostasic is an 18F-based agent listed in NCCN guidelines and has contributed to sales since Q1 2026. In therapeutic radiopharmaceutical CDMO, the company expects entry by global pharmaceutical companies to raise production demand.

Because radioisotopes have short half-lives, local infrastructure that enables supply immediately after production is cited as a key condition.

Diagnostic demand can be tracked through prescription and test volumes, while the competitive picture in therapeutic CDMO will be assessed as the Jeongeup plant approaches operation.

06

Outlook

On August 18, 2026, the company said that if the second-half trend continues, annual 2026 revenue could reach a record high. The comparison base is annual 2025 revenue of KRW 38.6 billion, and H1 2026 revenue of KRW 20.9 billion rose 16.3% year-over-year.

The Jeongeup CDMO plant is a two-phase project under an investment agreement with Jeonbuk State and Jeongeup City, with total investment of KRW 34.3 billion through 2032. Phase one commits about KRW 13.6 billion, with construction targeted to start in June 2027 and commercial production in the second half of 2029.

Phase two adds about KRW 20.7 billion from 2031 through the end of 2032 to build a radioisotope manufacturing center, an API manufacturing center and manufacturing plant No. 2.

Funding is planned from roughly KRW 19.3 billion of equity and about KRW 15 billion of facility borrowing, and the company says it will not conduct a rights offering.

An August 2026 report described up to KRW 50 billion of investment in R&D and CDMO facilities, with approval in 2028 and commercial production in 2030, so the two reports differ on scope and timing, and the annual report is where the confirmed plan will appear.

Dementia diagnostic production capacity is currently about 90,000 doses a year, and the company plans to add 120,000 doses by 2028 to reach 210,000.

In a January 2026 interview, Vice Chairman Kim Jong-woo estimated 2026 dementia diagnostic sales at about KRW 14 billion on the premise that insurance reimbursement had not been applied.

The company presented annual sales above KRW 20 billion at the Jeongeup plant as a target after phase two is complete at the end of 2032.

07

Valuation

PER
21.9×
PBR
2.9×
ROE
14.0%
EPS
₩245
BPS
₩1,878
Dividend per share
₩0

Valuation multiples move with the share price every day, so the comparison here is only between levels. Market capitalization sits well above total equity of KRW 49.2 billion at end-2025, which means the price carries a large premium over book net assets.

The price-to-earnings multiple reflects a year in which controlling-shareholder net profit declined and quarterly earnings moved around, so it reads as a high multiple relative to current earnings, and its interpretation depends on how quickly earnings recover.

The dividend yield is below the sector average, and the company has said the Jeongeup investment will be funded from cash on hand, operating cash flow and facility borrowing.

The rising share of the three diagnostic products, at 36.2% of H1 2026 revenue, is the premise for reading the multiples as the earnings mix shifts toward diagnostics.

Because controlling-shareholder net profit over the last four quarters totaled KRW 6.94 billion, earnings-based multiples are sensitive to quarter-to-quarter swings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Alzheimer's diagnostic share and output growth

The company said in May 2026 that it holds more than 94% of the domestic amyloid PET diagnostic market. Its 2025 production-value share for Alzheimer's diagnostics was 96.3%, the highest in three years, and output growth for the two products rose from 12% in 2024 to 55% in 2025. The company expects test demand to increase further if Kisunla receives approval.

2025 profit improvement and record quarterly sales

Operating profit rose 46.6% to KRW 7.44 billion in 2025, and the operating margin of 19.3% was the highest of the three years. Q2 2026 revenue of KRW 11.2 billion was reported as the company's highest quarterly sales.

H1 2026 revenue reached KRW 20.9 billion, up 16.3%, and the three diagnostic products accounted for 81% of the H1 revenue increase.

Jeongeup CDMO and pipeline expansion

The company plans to invest KRW 34.3 billion in a radiopharmaceutical CDMO plant and R&D center in Jeongeup, with construction targeted for June 2027 and commercial production in the second half of 2029. It describes annual capacity of about 1,000 batches as the largest among its production facilities.

Its in-house candidates DCB001 and DCB002, along with 177Lu-DOTATOC co-developed with ITM, make up the therapeutic pipeline.

09

Bear factors

Quarterly profit volatility and slower operating growth

Net profit attributable to controlling shareholders fell 18.9% to KRW 6.48 billion in 2025, and Q1 2026 operating profit of KRW 1.26 billion dropped 57.9% from the prior quarter.

In Q2 2026, operating profit growth trailed revenue growth, which the company tied to a base effect from one-time high-margin sales in the prior year and higher bad-debt and R&D expenses.

Q3 2026 operating profit of KRW 1.9 billion was down 0.2% year-over-year, so revenue growth has not yet translated into operating profit growth.

Concentration in diagnostics and policy variables

Revenue is concentrated in Alzheimer's and cancer diagnostics, so results are sensitive to test volumes and changes in the prescribing environment.

In a January 2026 interview, Vice Chairman Kim Jong-woo estimated 2026 dementia diagnostic sales at about KRW 14 billion on the premise that insurance reimbursement had not applied. New treatments may lift test demand, but the revenue structure could shift with insurance coverage and policy changes.

Investment burden and rising leverage

The debt-to-equity ratio rose from 51.5% in 2024 to 57.8% in 2025, with total liabilities of KRW 28.4 billion at end-2025. The Jeongeup investment is planned with about KRW 19.3 billion of equity and about KRW 15 billion of borrowing, so debt service could weigh on the balance sheet.

Commercial production is targeted for the second half of 2029, and the investment scale and timing reported in August and September 2026 differed, so the execution plan still needs firming up.

10

Risk factors

Regulatory and licensing

The CDMO plant must complete factory registration, MFDS GMP compliance review and Nuclear Safety and Security Commission production approval before commercial output. A delay at any stage could push back the second-half 2029 start target, and handling radioactive materials lengthens the approval path.

Product concentration and policy dependence

Most diagnostic revenue comes from Alzheimer's and cancer tests, leaving the company exposed to insurance policy, the reform of early dementia screening and the pace of new drug prescribing. A high domestic share also means that any shrinkage of the market would hit revenue more directly.

Ownership structure and share float

Its largest shareholder held 51.55% as of end-December 2025, and the largest shareholder group held 60.87% in total. MBK Partners exercises indirect control through that shareholder, so changes in management control or a stake sale could affect the free float and share price movement.

11

What to watch next

  1. By end-December 2026

    Whether Kisunla receives domestic approval. A May 2026 report expected approval within the year, and approval would raise pre-treatment amyloid PET demand, directly linked to Alzheimer's diagnostic sales.

  2. Around late January 2027

    The preliminary full-year 2026 results. The 2025 preliminary results were announced on January 29, 2026, so a similar timing is expected. The release will show whether 2026 revenue exceeds KRW 38.6 billion and whether the company's record annual sales target is met.

  3. By end-March 2027

    Filing of the 2026 annual report. It will confirm Q4 and full-year 2026 operating margin, debt-to-equity ratio and operating cash flow, and will show whether controlling-shareholder net profit recovers to KRW 6.48 billion and the amounts of non-operating items.

  4. June 2027

    Whether construction starts at the Jeongeup RPT CDMO plant. Phase one spending of about KRW 13.6 billion and the funding plan from equity and borrowing must line up with the actual construction schedule.

  5. By 2028

    The target date for raising dementia diagnostic capacity from 90,000 to 210,000 doses. The key test is whether added capacity translates into utilization and revenue growth.

12

Overall view

DuChemBio's DART-filed results for 2023-2025 show revenue rising in both 2024 and 2025 to KRW 38.6 billion, and operating profit rising 46.6% to KRW 7.44 billion in 2025 with a 19.3% margin.

Quarterly revenue stayed at high levels in 2026, with KRW 11.2 billion in Q2 and KRW 11 billion in Q3, while operating profit moved from KRW 1.26 billion in Q1 to KRW 1.93 billion in Q2 and KRW 1.9 billion in Q3.

Controlling-shareholder net profit fell in 2025 and has risen for two consecutive quarters since Q1 2026, though the last four quarters total KRW 6.94 billion.

Market share and output growth in Alzheimer's diagnostics are the strengths, while the move into therapeutic CDMO is a long-term project whose revenue contribution starts only after commercial production in the second half of 2029.

The investment is planned to be funded by equity and borrowing, and the debt-to-equity ratio rose to 57.8% in 2025 from 51.5% in 2024. With strengths and weaknesses both present, the next checkpoints are the full-year 2026 results, the Kisunla approval decision and the Jeongeup construction schedule.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thebionews.net
  2. sports.khan.co.kr
  3. etoday.co.kr
  4. pharmnews.com
  5. thelec.kr
  6. m.news.nate.com
  7. smarttoday.co.kr
  8. newspim.com
  9. thebionews.net
  10. thebionews.net
  11. comp.fnguide.com
  12. kr.investing.com
  13. pharm.edaily.co.kr
  14. seoul.co.kr
  15. en.edaily.co.kr
  16. view.asiae.co.kr
  17. v.daum.net
  18. hankyung.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis